

CONTENTS

Preface	(vii)
Acknowledgements	(ix)
List of Abbreviations	(xxi)

01 The Pharmaceutical Market

1

World Pharmaceutical Market, Key Drivers, Brakes, The Turf, Research-based Pharma Industry, The Generic Drug Industry, Evolution of a Research-based Drug Company, The Turf Wars, Surviving Patent Expiration: Defensive Strategies by the Big Pharma, Exploiting Patent Expiries: Generic Drug Firms' Offensive Strategies, Voluntary Licensing (VL) - An Alternate Strategy? Compulsory Licensing, Paragraph IV Filing, Lessons, Market Opportunity Analysis, Elements of Market Opportunity Analysis, Market Opportunity Analysis: A Step-by-Step Approach, Market Opportunity Analysis: An Example, The Served Market, Difficult Task, Defining Your Served Market: A Checklist, Market Segmentation: Points to Ponder, Strategic Options, A. Concentrated Marketing, B. Differentiated Marketing, C. Un-differentiated Marketing

Cases:

1. Prozac: The World's Leading Antidepressant Could not Survive its Patent Expiry Blues! **16**
2. Dr. Reddy's Exploits a Loophole in the Patent Term Extension Act! **18**
3. Biovail Buys Cardizem Patent, Breathes New Life into it! **19**
4. Natco Pharma Gets the First-Ever Compulsory License for Generic Nexavar in a Landmark Decision! **20**

(xii) | Contents

5. Anti-tubercular Market: A Tale of Two Companies! **23**
6. Anti-tubercular Market: Exploiting the Opportunities - The Secret of Lupin's Success! **25**
7. Once A Leader, Not Always A Leader! **26**
8. One Company's Complacency, Another Company's Vision! **28**
9. You Cannot Be Immune to Change, Even If You Are A Leader in Immunologicals! **30**
10. Booster Doses Are Essential To Boost Sales And Market Share! **32**
11. One is Enough! **34**
12. Opportunity Overlooked? **37**
13. Antacid Market: Emergence of A new Leader! **44**
14. Schering A.G. Concentrates on Gynaec Market and Beats the Retreat in Time! **48**

02 **The Pharmaceutical Product**

53

The Product Concept, What is a Brand? The Augmented Product Concept, Product Augmentation in the Indian Pharmaceutical Industry, Language of Branding, A Rose by Any Other Name, Product Life Cycle, Key Questions, Usefulness of Product Life Cycle, Market Life Cycle, Extending Product Life Cycle, Determining the Phase of Your Brand in the PLC, New Product Adoption Process, Three Major Propositions, The Individual Adoption Process, Adopter Categories, Product Life Cycle and Adoption Process, Implications for the Marketer, Product Portfolio Analysis, Boston Matrix, Portfolio Analysis in Pharmaceutical Marketing, Product Positioning, Why is Positioning a Must? Positioning Prescription Drugs, Positioning: A Definition, Positioning and Target Market Selection, Sustainable Differential Advantage, Key Questions, Ground Rules for Positioning, Lessons, Product Policy and Strategy, Governing Factors, New Products, Product-mix Decisions, Optimal Product-mix, Product Strategy, Market Penetration and Market Development Strategies, Product Development, Diversification, New Drug Adoption by Physicians in Branded Generic Markets: A Two-step Approach, Communication Hierarchy and the Adoption Process, Product Management, Management by Persuasion, Product Manager as a Gardener? Some Problem Areas, Product Management in the Indian Pharmaceutical

Industry, Making Product Management More Effective, Managing New Products, Standing Still is Going Backwards, The Costliness of New Product Development Process, Types of Risks, Why Develop New Products? The Importance of New Products on Profits, A Program for New Product Evolution, Basic Principles, New Product Development Process, Evaluating New Products, New Product Performance Review, Organizing for Success

Cases:

15. The Silent Salesman Adds Value! **59**
16. Innovation Makes All the Difference! **60**
17. The Brand that Catapulted a Company into the Top Position! **63**
18. The Impossible Name! **69**
19. Anti-tubercular Market Extends its Market Life Cycle While Eradicating Tuberculosis! **76**
20. The Centurion Gets Younger and Stronger by the Year! **80**
21. Anti-allergic Stimulates Appetite for Growth! **83**
22. New Indication Widens the Growth Spectrum! **84**
23. New Indication Attacks Competing Brands while Preventing Heart Attacks! **85**
24. The Antacid that Neutralized Even the Competition! **87**
25. Dr. Reddy's Laboratories and the Cost Leadership! **98**
26. The Fabulous Success Story of American Remedies in the Systemic Anti-Fungal Market! **110**
27. Undermining Others' Differential Advantage? **112**
28. Precise Positioning Improves the Blood Picture of Two Brands in the Hematinic Market! **115**
29. Clear Positioning Steers Glaxo Clear in Anti-Asthmatic Market! **117**
30. The New Antacid's Guerrilla Warfare! **119**
31. Alert makes it Good! **121**
32. Repositioning Strategy Replaces an Entrenched Brand! **122**
33. Me-too Strategy Meets with a Disaster! **124**
34. Synergistic Power of a Successful Repositioning Strategy! **125**
35. Rocephin Stands Out in a Crowded Market! **126**
36. Late Entrant Emerges As a Leader in a Crowded Market Place! **129**
37. Poor Diagnosis Proves Dearer! **143**
38. Unrelated Diversification Eludes Success for an Otherwise Highly

(xiv) | Contents

- Successful Company! **149**
- 39. Fasigyn Gives A Shot-in-the-arm to Tinidazole! **155**
- 40. Pioneer Fails to Take Off! **157**
- 41. Zinetec's Cakewalk! **159**
- 42. The Plight of a Profit Manager! **168**
- 43. Unique Brand of Brand Managers! **171**
- 44. Tagamet Pushes SmithKline into the Forefront! **178**
- 45. Zantac Wins the Anti-ulcer Race! **179**
- 46. Cadila's Climb! **181**
- 47. Ranbaxy's Runaway Progress! **184**
- 48. Lupin's Leap-frogging! **186**
- 49. Torrent - True to its Name! **188**

03 Therapeutic Leadership

207

Building A Disease Franchise for Achieving Therapeutic Leadership, Why Therapeutic Leadership? Defensible Strategy, From Niche to Franchise Enduring Success

Cases:

- 50. Eli Lilly's 90-Year Old Diabetes Franchise! **212**
- 51. The Everlasting Life of Xylocaine (Lidocaine)! **215**
- 52. The Brand That Helped The Company in Building A Franchise in Neurology! **217**
- 53. Johnson & Johnson Extends its Antipsychotic Franchise Strategically! **221**
- 54. Ranbaxy Defends its Leadership Position by Updating Its Products in the Urological the Market! **225**
- 55. Sovaldi's Unprecedented Launch Success Leads to a Therapeutic Leadership with its HCV Franchise! **227**

04 Product Launch Strategy

235

New Product Launch, Success Secrets, Making Your Drug Launch A Success, Factors That Shape Launch: A Checklist

Cases:

- 56. Exubera's Irrational Exuberance! **245**
- 57. Zelnorm: A Case of Misplaced Hopes **249**
- 58. Xigris Ends its Ten-Year Odyssey **251**
- 59. Highly Effective Launch of Januvia and Janumet by MSD in India **253**
- 60. Acomplia Beats A Hasty Retreat Without Accomplishing! **257**

05 Life Cycle Management

259

Life Cycle Management, Drug Life Optimization, Drug Life Optimization: Key Tactics, Ten Commandments of Life Cycle Management

Cases:

- 61. Bayer Manages the Life Cycle of 'Cipro' in Copybook Style! **266**
- 62. Merck Wins The Diabetes Race With A First Class Strategy For Its First-in-class Diabetes Drug! **270**
- 63. Prilosec, The Famous Heartburn Drug Causes Heartburn to its Competitors! **284**
- 64. Humira, The Swiss-Army Knife among Prescription Drugs! **291**
- 65. How A Fifth-in-Class Drug Became The Best-Selling Drug in the World! **296**

06

Pharmaceutical Marketing Practices: Good and Bad

311

Declining Reputation Good Practices, Pharma's Bad Practices, Factors Associated With Reputational Damage, The TARES Test

Cases:

- 66. Marketing Through Manipulation and Misinformation! **320**
- 67. The Vioxx Fiasco! **329**
- 68. The Rise and Fall of Baycol **336**
- 69. Prozac: A Classic Example of Marketing Excellence! **341**
- 70. The Rise of the Weekend Pill! **349**
- 71. Glaxo, The House That Zantac Built! **359**
- 72. Gardasil - Marketing Success or Missed Opportunity? **368**
- 73. BiDiI: Rational Medicine or Racial Medicine? **374**
- 74. The First Rationally Designed Small Molecule Drug of Novartis Wins the 'Prestigious Prix Galien Foundation's' Discovery of the Decade Award in 2016! **380**

07

Disease Branding

387

Disease Branding, Origins of Disease Branding, Dual Advantages, Three Strategic Approaches, Five Questions, Benefits of Disease Branding

Cases:

- 75. Pharmaceutical Industry Learns the Art of Disease Branding From the Father of Public Relations in America! **390**
- 76. Pharma's First Shot at Disease - Branding! **394**
- 77. The Mother of All Disease Awareness Campaigns! **397**
- 78. The Birth of A New Condition - GERD! **399**

- 79. Upjohn's Efforts in Disentangling of Panic Disorders From Anxiety Disorders Pay Handsome Dividends! **401**
- 80. Pfizer Eliminates the Stigma Surrounding Impotence with an Acronym! **403**
- 81. Eli Lilly Fields A Second Brand of the Same Drug for A Branded Condition! **405**
- 82. Positioning A Brand by Creating A Disease! **408**
- 83. A Disorder Made to Order! **415**
- 84. Pfizer, PTSD, and Zoloft! **418**
- 85. Merck Creates A Market for A Bone Disease, Fields Its New Drug, Fosamax And Makes it the Market Leader! **420**
- 86. Two Stories: How ADHD Was Sold and How Two Brands Dominated the ADHD Market! **429**

08 Blue Ocean Strategy

445

Blue and Red Oceans, Value Innovation, Henry Ford Creates A Blue Ocean, How to Formulate A Blue Ocean Strategy, The PMS Map, Blue Ocean Strategy: Key Questions, Identifying Non-Customers

Cases:

- 87. Novo Nordisk's Blue Ocean Strategy **454**
- 88. The Little Blue Pill's Astonishing Dream Run! **457**
- 89. Requip's Success Recipe: Brand A Disease, Market a Treatment! **472**
- 90. Mankind Pharma: Changing the Rules of the Game! **476**

09 The Pricing Strategies

483

Price and Pharma Marketing Mix, Pricing Objectives, Pricing Decisions, Bases for Pricing, Cost-based Pricing, Demand-based Pricing, Competition-based Pricing, Price Comparison, Market-based Pricing, Pricing Strategies, Skim the cream Strategy, Penetration Strategy, Marginal Cost Price Changes, Strategy, Pricing Management, Customers' Reactions to Price Changes, Price Communicates, Psychological Effects of Pricing, Desensitizing the Consumer to Price, Predatory Pricing: An Emerging Trend, 'Me-too' Pricing Strategy for 'Me-too' Products, Periodical Review

Cases:

91. How Glaxo Won the Anti-Ulcer Market! **496**
92. Mankind Pharma Storms into Indian Pharmaceutical Market with its Penetrative Pricing! **498**
93. Predatory Pricing in Pharmaceutical Industry **504**
94. Awareness Campaigns, Lobbying, Legislation, Competitors' Stumbles and Exorbitant Price Hikes Make A Blockbuster! **506**

10 Pharma and Social Media

511

What is Social Media? Social Media Marketing, Physicians on Social Media, Patients Are In Control, Insights From Social Media Conversations, Challenging Regulatory Environment, FDA Guidance on Social Media: Implications for Pharma, How Can Pharma Comply with the FDA Guidance on Social Media? Pharma Must Embrace Social Media, 6 Ways Pharma May Use Social Media, Content is King! Gamification, Five Key Elements, How Gamification is Beneficial, More Apps, Slow Rate of Adoption, Engagification, not Gamification! Pharma and Social Media: the Indian Scenario, Presence Vs Engagement, Patients on Social Media, Physicians on Social Media, Digital Initiatives of MNCs in India, Social Media and Indian Pharma, Social Media, Public Relations and Crisis Management, 13 Golden Rules of PR Crisis Management, Tylenol: A Classic Example of Crisis Management, Social Media in Crisis Management

Cases:

- 95. How Kim Kardashian's instagram Post Got the Drug Firm That Makes "Diclegis" into Trouble with the FDA. **516**
- 96. Facebook-Share Function Gets A Warning From the FDA! **518**
- 97. Suprenza's False Claims Ring An Alarm! **519**
- 98. Janssen's *Me Without Migraine* Patient Awareness Campaign **525**
- 99. Sanofi Has Got Game! **532**
- 100. Tylenol Scandal and Crisis Management **547**

Key Insights, and Practical Lessons 549

References 563

Index 583

About the Author 595